Efficacy of neoadjuvant pembrolizumab combined with paclitaxel and cisplatin in locally advanced oropharyngeal and hypopharyngeal squamous cell carcinoma: a retrospective study
In locally advanced OPHSCC, neoadjuvant pembrolizumab combined with paclitaxel and cisplatin showed a higher ORR and increased transoral surgery rates while preserving laryngeal function, with no increase in severe treatment-related adverse events, demonstrating favorable efficacy and safety profiles.
Authors
- Shaowen Tang (ORCID: https://orcid.org/0000-0001-5879-8594)
- Zhihong Chen (ORCID: https://orcid.org/0000-0002-7056-1335)
- Xiaobo Wu (ORCID: https://orcid.org/0000-0002-4786-4637)
- Gongbiao Lin (ORCID: https://orcid.org/0000-0002-9333-9868)
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1690935
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fujian Medical University